



2021 年五月份會議

日期：2021 年 5 月 27 日 (星期四)

地點：(WebEX 視訊方式)

議程：

時 間	主 題	主 講 人
13:15 ~ 13:30	請提早上線，以確保準時加入會議	
13:30 ~ 13:40	會務報告	黃麗榕 理事長
13:40 ~ 14:10	Task Force 報告	Task Force Leads & Co-Leads ♦ EC – Hockey/Vivi/Claire/Anchi ♦ C&C – Muting/Ariel/Zoe/Carol ♦ GA – Iris/Mandy/Cherri/Lee-Hsin ♦ EDU – Tina/Emily/Molly
14:10~14:40	Sharing under COVID-19 pandemic : 會員公司分享	劉明哲主任(北醫 JCRC) Anchi Huang(Bayer) Emily Lin(QPS)
14:40 ~ 14:50	臨時動議 & Wrap up	黃麗榕 理事長
14:50 ~ 15:00	Break	
15:00 ~ 16:30	專題演講 ❖ The mRNA Vaccine – The New Era of Vaccinology	Carlos Linn, MD Senior Director Global Lead Clinician, Immuno-Oncology Pfizer, Inc.

Speaker Introduction :

Carlos Linn, MD / Senior Director Global Lead Clinician, Immuno-Oncology | Pfizer, Inc.

Carlos Linn is currently the Senior Director, Global Oncology (Immune-oncology, IO) Lead Clinician, Global Product Development (GPD), Pfizer, Inc. He is now managing clinical development, safety surveillance, and medical oversight for clinical integrity on a couple of global Phase 1b, 1/2, and 3 studies of immune-oncology therapeutic area, including the investigational products of gemtuzumab ozogamicin (CD-33 antibody-drug conjugate, ADC), talazoparib (PARP inhibitor), avelumab (Anti-PD-L1 monoclonal antibody), sasanlimab (Anti-PD1 monoclonal antibody), and the recent secondment of COVID-19 vaccine candidate (BNT162b2).



Carlos received his Doctor of Medicine (M.D.) from National Yang-Ming University, Taipei, Taiwan, in 1993 and has been appointed as a clinical assistant professor (adjunct) of National Yang-Ming University since 2005. After his 12-year clinical practice at Taipei Veterans General Hospital, he started the industry career at Eli Lilly Taiwan as an oncology clinical research physician in 2005, then moved to regional clinical research role in 2008. He joined Pfizer as the regional medical director, oncology, Asia/China in 2012, China clinical development lead, oncology in 2014, and moved to global lead clinician, oncology/immune-oncology in 2017. He has rich experience in new drug development in Asia Pacific, China, Japan, and global execution.